Do analysts prefer VVOS or RVP?

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 769.57%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LFWD or VVOS more profitable?

Lifeward has a net margin of -123.66% compared to Vivos Therapeutics' net margin of -127.70%. Lifeward's return on equity of -243.14% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lifeward -123.66% -243.14% -97.39% Vivos Therapeutics -127.70% -2,325.64% -98.12%

Does the media favor LFWD or VVOS?

In the previous week, Lifeward had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for Lifeward and 2 mentions for Vivos Therapeutics. Lifeward's average media sentiment score of 1.33 beat Vivos Therapeutics' score of 0.00 indicating that Lifeward is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifeward 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VVOS or IRIX more profitable?

IRIDEX has a net margin of -6.23% compared to Vivos Therapeutics' net margin of -127.70%. IRIDEX's return on equity of 0.00% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vivos Therapeutics -127.70% -2,325.64% -98.12% IRIDEX -6.23% N/A -11.16%

Does the media prefer VVOS or IRIX?

In the previous week, Vivos Therapeutics had 1 more articles in the media than IRIDEX. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for IRIDEX. Vivos Therapeutics' average media sentiment score of 0.00 equaled IRIDEX'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IRIDEX 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VVOS or NMTC?

In the previous week, Vivos Therapeutics and Vivos Therapeutics both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VVOS or OSRH?

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 769.57%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, VVOS or OSRH?

Vivos Therapeutics has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vivos Therapeutics $19.57M 0.23 -$21.17M -$2.14 N/A OSR $2.91M 5.26 -$27.06M -$0.33 N/A

Is VVOS or OSRH more profitable?

Vivos Therapeutics has a net margin of -127.70% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vivos Therapeutics -127.70% -2,325.64% -98.12% OSR -363.26% -7.24% -5.41%

Does the media prefer VVOS or OSRH?

In the previous week, Vivos Therapeutics had 1 more articles in the media than OSR. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for OSR. OSR's average media sentiment score of 0.47 beat Vivos Therapeutics' score of 0.00 indicating that OSR is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OSR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vivos Therapeutics (VVOS) Competitors

$0.32 -0.02 (-5.46%)

Closing price 04:00 PM Eastern

Extended Trading

$0.32 +0.00 (+0.62%)

As of 06:40 PM Eastern

Compare

VVOS vs. RVP, LFWD, IRIX, NMTC, and OSRH

Should you buy Vivos Therapeutics stock or one of its competitors? MarketBeat compares Vivos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vivos Therapeutics include Retractable Technologies (RVP), Lifeward (LFWD), IRIDEX (IRIX), NeuroOne Medical Technologies (NMTC), and OSR (OSRH).

How does Vivos Therapeutics compare to Retractable Technologies?

Vivos Therapeutics (NASDAQ:VVOS) and Retractable Technologies (NYSE:RVP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Vivos Therapeutics has a beta of 6.22, meaning that its share price is 522% more volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Retractable Technologies has higher revenue and earnings than Vivos Therapeutics. Retractable Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.23	-$21.17M	-$2.14	N/A
Retractable Technologies	$37.15M	0.55	-$7.01M	-$0.21	N/A

Retractable Technologies has a net margin of -41.11% compared to Vivos Therapeutics' net margin of -127.70%. Retractable Technologies' return on equity of -17.15% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Retractable Technologies	-41.11%	-17.15%	-9.33%

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 769.57%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Vivos Therapeutics had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for Vivos Therapeutics and 0 mentions for Retractable Technologies. Vivos Therapeutics' average media sentiment score of 0.00 equaled Retractable Technologies'average media sentiment score.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Retractable Technologies	Neutral

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 59.5% of Retractable Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Retractable Technologies beats Vivos Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to Lifeward?

Lifeward (NASDAQ:LFWD) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Lifeward has a net margin of -123.66% compared to Vivos Therapeutics' net margin of -127.70%. Lifeward's return on equity of -243.14% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-123.66%	-243.14%	-97.39%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Lifeward has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.22, meaning that its stock price is 522% more volatile than the broader market.

26.8% of Lifeward shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 1.5% of Lifeward shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifeward has higher revenue and earnings than Vivos Therapeutics. Lifeward is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.94	-$19.91M	-$19.66	N/A
Vivos Therapeutics	$19.57M	0.23	-$21.17M	-$2.14	N/A

In the previous week, Lifeward had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for Lifeward and 2 mentions for Vivos Therapeutics. Lifeward's average media sentiment score of 1.33 beat Vivos Therapeutics' score of 0.00 indicating that Lifeward is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifeward currently has a consensus target price of $10.00, suggesting a potential upside of 36.33%. Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 769.57%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Lifeward beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to IRIDEX?

Vivos Therapeutics (NASDAQ:VVOS) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

IRIDEX has a net margin of -6.23% compared to Vivos Therapeutics' net margin of -127.70%. IRIDEX's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
IRIDEX	-6.23%	N/A	-11.16%

IRIDEX has higher revenue and earnings than Vivos Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.23	-$21.17M	-$2.14	N/A
IRIDEX	$52.67M	0.28	-$4.44M	-$0.19	N/A

Vivos Therapeutics presently has a consensus target price of $2.80, indicating a potential upside of 769.57%. IRIDEX has a consensus target price of $3.00, indicating a potential upside of 257.31%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Vivos Therapeutics is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 8.6% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vivos Therapeutics had 1 more articles in the media than IRIDEX. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for IRIDEX. Vivos Therapeutics' average media sentiment score of 0.00 equaled IRIDEX'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IRIDEX	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vivos Therapeutics has a beta of 6.22, suggesting that its share price is 522% more volatile than the broader market. Comparatively, IRIDEX has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Summary

IRIDEX beats Vivos Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Vivos Therapeutics (NASDAQ:VVOS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

NeuroOne Medical Technologies has lower revenue, but higher earnings than Vivos Therapeutics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.23	-$21.17M	-$2.14	N/A
NeuroOne Medical Technologies	$9.72M	1.39	-$3.61M	-$0.85	N/A

NeuroOne Medical Technologies has a net margin of -68.35% compared to Vivos Therapeutics' net margin of -127.70%. NeuroOne Medical Technologies' return on equity of -99.43% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 769.57%. NeuroOne Medical Technologies has a consensus target price of $11.67, suggesting a potential upside of 652.69%. Given Vivos Therapeutics' higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vivos Therapeutics has a beta of 6.22, meaning that its share price is 522% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

In the previous week, Vivos Therapeutics and Vivos Therapeutics both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeuroOne Medical Technologies beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Vivos Therapeutics compare to OSR?

Vivos Therapeutics (NASDAQ:VVOS) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 36.9% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vivos Therapeutics has a beta of 6.22, meaning that its stock price is 522% more volatile than the broader market. Comparatively, OSR has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

In the previous week, Vivos Therapeutics had 1 more articles in the media than OSR. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for OSR. OSR's average media sentiment score of 0.47 beat Vivos Therapeutics' score of 0.00 indicating that OSR is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OSR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vivos Therapeutics has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.23	-$21.17M	-$2.14	N/A
OSR	$2.91M	5.26	-$27.06M	-$0.33	N/A

Vivos Therapeutics has a net margin of -127.70% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
OSR	-363.26%	-7.24%	-5.41%

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 769.57%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vivos Therapeutics beats OSR on 9 of the 16 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.47M	$5.72B	$6.93B	$12.84B
Dividend Yield	N/A	1.78%	2.60%	9.78%
P/E Ratio	-0.15	24.74	281.16	25.43
Price / Sales	0.23	63.14	577.53	82.47
Price / Cash	N/A	32.67	71.79	50.79
Price / Book	-2.01	6.02	12.86	6.06
Net Income	-$21.17M	$152.55M	$3.49B	$348.34M
7 Day Performance	-20.67%	3.36%	2.64%	3.03%
1 Month Performance	-33.26%	-1.73%	-2.64%	-3.04%
1 Year Performance	-93.05%	8.89%	76.00%	20.65%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	1.5357 of 5 stars	$0.32 -5.5%	$2.80 +769.6%	-93.1%	$4.47M	$19.57M	N/A	160	News Coverage
RVP Retractable Technologies	N/A	$0.68 +0.7%	N/A	-8.2%	$20.21M	$37.15M	N/A	240
LFWD Lifeward	2.503 of 5 stars	$6.99 -1.7%	$10.00 +43.1%	-12.9%	$20.02M	$22.03M	N/A	60	News Coverage Positive News Upcoming Earnings Analyst Upgrade
IRIX IRIDEX	1.4151 of 5 stars	$0.88 -0.9%	$3.00 +240.5%	-35.3%	$15.47M	$52.58M	N/A	120
NMTC NeuroOne Medical Technologies	2.4844 of 5 stars	$1.67 -5.1%	$11.67 +598.6%	-66.1%	$15.32M	$12.10M	N/A	20	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. RVP, LFWD, IRIX, NMTC, and OSRH

How does Vivos Therapeutics compare to Retractable Technologies?

Summary

How does Vivos Therapeutics compare to Lifeward?

Summary

How does Vivos Therapeutics compare to IRIDEX?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Summary

How does Vivos Therapeutics compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. RVP, LFWD, IRIX, NMTC, and OSRH

How does Vivos Therapeutics compare to Retractable Technologies?

Which has more volatility & risk, VVOS or RVP?

Which has better valuation and earnings, VVOS or RVP?

Is VVOS or RVP more profitable?

Do analysts prefer VVOS or RVP?

Does the media favor VVOS or RVP?

Do insiders and institutionals hold more shares of VVOS or RVP?

Summary

How does Vivos Therapeutics compare to Lifeward?

Is LFWD or VVOS more profitable?

Which has more risk & volatility, LFWD or VVOS?

Do insiders & institutionals believe in LFWD or VVOS?

Which has better earnings and valuation, LFWD or VVOS?

Does the media favor LFWD or VVOS?

Do analysts recommend LFWD or VVOS?

Summary

How does Vivos Therapeutics compare to IRIDEX?

Is VVOS or IRIX more profitable?

Which has stronger earnings and valuation, VVOS or IRIX?

Do analysts rate VVOS or IRIX?

Do institutionals & insiders believe in VVOS or IRIX?

Does the media prefer VVOS or IRIX?

Which has more volatility & risk, VVOS or IRIX?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Which has better earnings and valuation, VVOS or NMTC?

Is VVOS or NMTC more profitable?

Do analysts recommend VVOS or NMTC?

Do institutionals and insiders hold more shares of VVOS or NMTC?

Which has more volatility and risk, VVOS or NMTC?

Does the media prefer VVOS or NMTC?

Summary

How does Vivos Therapeutics compare to OSR?

Do insiders & institutionals hold more shares of VVOS or OSRH?

Which has more volatility & risk, VVOS or OSRH?

Does the media prefer VVOS or OSRH?

Which has stronger earnings & valuation, VVOS or OSRH?

Is VVOS or OSRH more profitable?

Do analysts recommend VVOS or OSRH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools